Bio Medica Laboratories' initial public offering begins subscription on Thursday, May 21, with the issue scheduled to close on May 25. According to reports from The Economic Times and PNN, the company plans to raise ₹52.43 crore through a combination of fresh issue and offer-for-sale components. The shares are expected to list on the NSE Emerge Platform on May 29. As per the latest reports, the allotment date is scheduled for May 26, 2026. Mr. Pradeep Mehta, Managing Director, stated that the launch marks a significant milestone, with proceeds supporting expansion and upgradation of manufacturing facilities to enhance production capabilities.
The company has fixed the price band at ₹132-139 per share, with grey market activity indicating a 0% premium ahead of the launch. As reported by The Economic Times, investors can bid for a minimum of 1,000 shares, but retail investors must apply for at least 2,000 shares (2 lots), translating to a minimum investment of ₹2.78 lakh at the upper price band. Small HNI investors require a minimum application of 3,000 shares worth ₹4.17 lakh. The issue structure includes QIB allocation of up to 36,000 shares, NII allocation of at least 17,55,000 shares, RII allocation of at least 17,92,000 shares, and market maker allocation of 1,89,000 shares.
The IPO comprises a fresh issue of 33.95 lakh shares aggregating to approximately ₹47.19 crore and an offer for sale of 3.77 lakh shares worth around ₹5.24 crore. According to The Economic Times and PNN, the issue is managed by Narnolia Financial Services as the book-running lead manager and Skyline Financial Services as the registrar. The net proceeds will be utilized towards repayment of loans, enhancement of existing production capabilities by setting up a new manufacturing facility at the existing premises, and general corporate purposes.
Incorporated in 2015, Bio Medica Laboratories operates as a pharmaceutical contract manufacturing company with a B2B business model. The company manufactures pharmaceutical parenteral formulations including injectable drugs for both human and veterinary healthcare segments, with a product portfolio of 58 liquid injectable products and 15 dry powder injectable products manufactured in single-dose and multi-dose formats. As reported by The Economic Times and PNN, the company operates its own research and development (R&D) center and focuses on GMP (Good Manufacturing Practices) and GLP standards to maintain high product quality and safety standards. The company operates two manufacturing units located in Indore, Madhya Pradesh, which are GMP & GLP certified by the Food & Drugs Administration, Madhya Pradesh. The company exports pharmaceutical products to foreign countries and healthcare markets outside India, catering to customers across 15 states and serving both domestic and export markets.
The company has demonstrated strong financial growth with revenue increasing from ₹16.22 crore in FY23 to ₹38.19 crore in FY25. EBITDA margins improved significantly from 10.54% in FY23 to 40.14% in FY25, while PAT margins expanded from 2.03% to 25.63% over the same period. EPS grew from ₹0.36 in FY23 to ₹10.67 in FY25, and ROE increased from 6.68% to 132.48% during this period. For November 2025, the company reported Revenue from Operations of ₹2,854.69 lakhs, EBITDA of ₹1,344.72 lakhs, and PAT of ₹866.39 lakhs. However, the company's total debt levels have risen from ₹9.60 crore in FY23 to ₹15.00 crore in FY25. Despite these strong financial metrics, investors should note that SME IPOs generally carry higher risk and volatility compared to larger listed companies.
